Novartis AG (NYSE: NVS) reports Thursday a 1 percent increase in third-quarter net profit on strong sales of pharmaceuticals, such as its new Afinitor drug against kidney cancer, according to Associated Press.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
The company raised its full-year outlook after the approval of its swine flu vaccines. The profit of $2.1 billion was up from $2 billion in the same period of 2008.
Earnings were largely offset by one-off charges, including the reduction of the value of a research and development project related to eye care company Alcon. Increased financing costs and a higher tax rate also prevented a better result, Novartis said.
Net sales were $11.1 billion, up 3 percent from $10.7 billion in the year-earlier quarter. Without the effect of the weaker dollar, net sales rose 7 percent in local currencies, the company said.
Novartis raised its 2009 outlook for net sales, saying they will grow at a high-single-digit rate in local currencies, even excluding anticipated sales of swine flu vaccines in the fourth quarter.
The approval in the U.S. and Europe for Novartis' swine flu vaccine will help boost performance, with 90 to 120 million doses expected to be produced by the end of the year. That is expected to increase fourth quarter net sales by $400 million to $700 million.
Shares in Novartis closed down 0.1 percent at 52.40 Swiss francs ($51.9) on the Zurich exchange, while they fell 42 cents to $52.13 in New York Stock Exchange trading.
Net sales in the pharmaceuticals division rose 8 percent to $7.2 billion, up from $6.7 billion in the year-earlier quarter. The growth was driven by sales of the new Afinitor drug against kidney cancer in the U.S. and other drugs, including the high blood pressure treatments Exforge and Tekturna, which is known as Rasilez outside of the U.S.
It noted that recently approved Lucentis, for patients with wet age-related macular degeneration, a form of blindness, and Tasigna, to treat certain forms of Philadelphia chromosome-positive chronic myeloid leukemia, compensated weakening performance of the hypertension drug Diovan in the U.S. as patients chose cheap generics.
Novartis said it expected pharmaceuticals net sales in local currencies to grow at a double-digit rate in 2009.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Us
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
